Pioneering Evidence-Based AI Innovation in Personalized Wellness and Health ResearchVANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs' commitment to rigorous s ...

Core Insights - Hims & Hers Health, Inc. (HIMS) is transforming health and wellness through a consumer-first digital platform, providing treatment for chronic and sensitive conditions, and has conducted over 30 million telehealth consultations in the U.S. and U.K. [1][7] Company Overview - HIMS offers accessible care for mental health, dermatology, sexual wellness, and weight management via its mobile app [7] - The company is expanding its services to include lab testing, compounded medications, and personalized digital wellness solutions [7] Industry Trends - According to McKinsey's 2025 Future of Wellness Trends survey, wellness is increasingly important to consumers, especially Gen Z and millennials, leading to a demand for accessible, science-backed, and personalized solutions [3] - Hims & Hers is well-positioned in the evolving wellness industry with a scalable, tech-enabled model that emphasizes individualized care and proactive health management [3] Competitive Landscape - LifeMD, Inc. (LFMD) focuses on direct-to-patient telehealth services for lifestyle and chronic health conditions, expanding its offerings in accessible digital healthcare [4] - Medifast, Inc. (MED) emphasizes lifestyle-based weight management through its OPTAVIA program, supporting over 25,000 active coaches and impacting over 3 million lives [5] Financial Performance - HIMS shares have increased by 90.6% year-to-date, significantly outperforming the industry growth of 9.9% [6] - The Zacks Consensus Estimate predicts a 174.1% increase in HIMS' earnings per share from 2024 to 2025 [8] Valuation Metrics - HIMS has a forward 12-month price-to-sales (P/S) ratio of 4.1X, which is lower than the industry average of 5.8X but higher than its three-year median of 2.3X [10]